KTKathrin Taxer

Kathrin Taxer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kathrin Taxer has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Harmonising the scope of practice for genetic counsellors in the D-A-CH region: a cross-border consensus for Germany, Austria, and Switzerland

    by Gunda Schwaninger, Kathrin Taxer, Wera Hofmann, Christophe Cordier, Camila Gabriel, Johanna Tecklenburg, Johannes Zschocke, Simone Heidemann

    Rapid integration of genomics into clinical practice has increased the demand for genetic counselling services. While the genetic counsellor (GC) profession is well established in the Anglo-American healthcare systems, the D-A-CH countries, Germany, Austria, and Switzerland, operate under distinct, physician-led legal frameworks. To ensure high-quality care and professional mobility, a harmonised definition of the GC's role is necessary. The newly founded GfH Commission for GCs, in collaboration with the national human genetics societies of Germany (GfH), Austria (ÖGH), and Switzerland (SGMG), the Association of German Human Geneticists (BVDH), and the Swiss Association of GCs (ASCG), conducted a multi-stage consensus-building process. The methodology involved a comparative analysis of national legal prerequisites and the application of the entrustable professional activities framework to define the interprofessional interface between GCs and medical geneticists (MGs). The resulting scope of practice (SoP) categorizes competencies across three clinical phases: pre-counselling preparation, the active counselling process, and post-analytical follow-up. The SoP distinguishes between independent GC tasks, shared clinical responsibilities, and tasks requiring MGs. Key to this model is the preservation of the legal physician-prerogative for aspects like the final medical diagnosis and test-ordering while maximizing the GC’s contribution to patient-centred communication and care. This cross-border consensus represents a landmark in European professional policy, providing a scalable blueprint for the integration of GCs into regulated medical systems. By harmonising standards across the D-A-CH countries, the SoP ensures quality assurance, provides a robust evidence base for future legislative recognition and reimbursement of GCs, and facilitates professional mobility in Europe. Genetic counsellor, professional policy, D-A-CH region, interprofessional collaboration, entrustable professional activities, scope of practice, Genetische Fachberater, GfH, ÖGH, SGMG, BVDH, ASCG


  • Open Access

    Reporting practices for secondary findings among ERN GENTURIS member institutions in 15 European countries

    by Kathrin Taxer, Katharina Wimmer, Karin Wadt, Simon Schnaiter, Sabine Rudnik, Johannes Zschocke, Svetlana Bajalica-Lagercrantz, Irma van de Beek, Hilde Brems, Robin de Putter, et al.

    Secondary findings (SF) identified in massive parallel sequencing raise important clinical and healthcare related questions. To get an overview on current practices of European healthcare providers (HCP), we conducted a cross-sectional survey study among 39 stakeholders—predominantly senior medical and laboratory geneticists—from 15 European countries participating in the European Reference Network for Genetic Tumour Risk Syndromes (ERN GENTURIS). Respondents reported considerable heterogeneity in SF management and reporting, even within countries. While 31% of responding HCP return findings from all 81 genes on the American College of Medical Genetics and Genomics (ACMG) recommended SF list version 3.2, 41% restrict SF disclosure, often excluding genes associated with cardiological or metabolic disorders or with limited clinical actionability. A further 26% do not report ACMG-listed SF at all. Notably, 70% of HCP also assess additional cancer-predisposition genes beyond the ACMG list, using in-house gene lists or national guidelines. Most HCP restrict reporting to (likely) pathogenic variants (90%) and find SF in less than 5% of genetic analyses (59%). Consent procedures and patient information practices varied, with most HCP employing opt-in consent models and genetic counselling primarily delivered by medical geneticists and genetic counsellors. Major institutional challenges raised by participants, include lack of harmonised guidelines, concerns about patient anxiety, and insufficient resources for follow-up care. The findings of this study highlight the need for robust, evidence-based European guidelines to ensure clinically relevant and patient-centred SF management.